secwatch.observer — SEC 8-K summary
======================================

Issuer:     BIOCRYST PHARMACEUTICALS INC (BCRX)
CIK:        0000882796
Form:       8-K
Filed at:   2025-06-04T23:59:59+00:00
Accession:  0001171843-25-003662
Event type: leadership
Sentiment:  neutral
Materiality: 0.50
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

BioCryst extends former CFO Anthony Doyle's consulting agreement through Dec 31, 2025
--------------------------------------------------------------------------------

- Consulting Agreement extended from original end date to December 31, 2025; after that, month-to-month with 30-day notice.
- Mr. Doyle provides transition services related to CFO succession at $450/hour; all other terms unchanged.
- Original agreement effective April 9, 2025; extension announced on May 31, 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/882796/000117184325003662/0001171843-25-003662-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/882796/000117184325003662/f8k_060325.htm
  HTML page:      https://secwatch.observer/filing/0001171843-25-003662

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer